In Australia, is Addyi (Flibanserin) available or what is available?
Australia Leads the Way in Androgen Treatment for Women with HSDD
While the US-approved drug flibanserin offers limited benefit for Hypoactive Sexual Desire Disorder (HSDD), it’s not approved in Australia—and comes with notable side effects.
Instead, Australia is the only country in the world to approve a regulated androgen hormone treatment specifically for postmenopausal women with HSDD. This topical therapy restores androgen levels to those typical of premenopausal women and is backed by decades of Australian-led research.
This marks a major step forward in addressing gender equity in sexual health care.
Latest News
PBAC says NO!
The outcome of the November 2025 meeting of the Pharmaceuticals Benefits Advisory Committee (PBAC) has determined that AndroFeme® 1 testosterone cream for the treatment… Continue Reading →
Have you heard of Responsive Desire?
Responsive Desire—A New Way to Think About Female Sexuality Not feeling spontaneous desire? That’s completely normal. Many women experience what’s called responsive desire—where arousal and… Continue Reading →
How to talk to your Doctor about Sexual Health
What is HSDD? Hypoactive Sexual Desire Disorder Hypoactive Sexual Desire Disorder (HSDD) is a recognised and common medical condition characterised by persistently low sexual… Continue Reading →